Q2 2024 EPS Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO) Reduced by Analyst
Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) – Equities researchers at Zacks Research cut their Q2 2024 EPS estimates for Halozyme Therapeutics in a research note issued to investors on Wednesday, February 7th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.81 per share for the quarter, down […]
More Stories
Oak Woods Acquisition Co. (NASDAQ:OAKUW) Sees Significant Decline in Short Interest
Oak Woods Acquisition Co. (NASDAQ:OAKUW – Get Free Report) was the recipient of a significant drop in short interest in...
PIMCO Municipal Income Fund III (NYSE:PMX) Short Interest Down 24.4% in October
PIMCO Municipal Income Fund III (NYSE:PMX – Get Free Report) was the recipient of a large decrease in short interest...
Enstar Group Limited (NASDAQ:ESGRO) Short Interest Update
Enstar Group Limited (NASDAQ:ESGRO – Get Free Report) saw a large drop in short interest during the month of October....
Crescent Energy (NYSE:CRGY) Short Interest Down 10.7% in October
Crescent Energy (NYSE:CRGY – Get Free Report) was the target of a significant drop in short interest in October. As...
Short Interest in East West Bancorp, Inc. (NASDAQ:EWBC) Decreases By 10.6%
East West Bancorp, Inc. (NASDAQ:EWBC – Get Free Report) saw a large decline in short interest during the month of...
Bilibili (NASDAQ:BILI) Announces Earnings Results
Bilibili (NASDAQ:BILI – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.57 earnings per share...